SS Innovations International, Inc. has received regulatory approval for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya, marking a significant expansion of the company's global footprint in medical technology. The approvals position the company to address what it describes as underpenetrated markets with a cost-effective alternative to established robotic surgery systems.
The company received approval from Colombia's Instituto Nacional de Vigilancia de Medicamentos y Alimentos in November 2025, Oman's Directorate General of Pharmaceutical Affairs and Drug Control in November 2025, Sri Lanka's National Medicines Regulatory Authority in January 2026, and Kenya's Pharmacy and Poisons Board in January 2026. These approvals add to existing regulatory clearances in seven other countries, bringing the total to eleven nations where the SSi Mantra can now be marketed and deployed.
This expansion matters because it represents a tangible step toward making advanced surgical robotics more accessible in regions where cost has traditionally been a barrier to adoption. Surgical robotic systems have revolutionized many procedures by enhancing precision and enabling minimally invasive techniques, but their high price has limited deployment primarily to wealthy healthcare systems. SS Innovations emphasizes the SSi Mantra's cost advantages combined with advanced technology as key differentiators that could democratize access to robotic surgery.
Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, stated that the company continues to expand its global opportunity with an eye on democratizing access to cutting-edge robotic surgery for patients in underserved regions. The company is pursuing regulatory pathways in established markets simultaneously, anticipating U.S. Food and Drug Administration review completion by mid-2026 and European Union CE marking certification potentially in 2026.
The SSi Mantra has demonstrated real-world application with an installed base of 168 systems across ten countries as of December 31, 2025, having performed 7,885 cumulative surgeries including 390 cardiac procedures and 121 pediatric surgeries. The system has also enabled more than 150 telesurgeries, highlighting its potential to extend surgical expertise remotely. The system's features include modular robotic arms, an ergonomic surgeon command center, 3D 4K visualization, and compatibility with over 40 different types of robotic instruments for various specialties.
For healthcare systems in the newly approved countries, this development could mean expanded surgical capabilities without the financial burden associated with more expensive robotic platforms. The implications extend beyond individual hospitals to national healthcare strategies, potentially enabling more patients to benefit from minimally invasive procedures that typically result in faster recovery times and reduced complications. The company's progress can be tracked through its website at https://ssinnovations.com where updates are regularly posted.
As healthcare systems worldwide seek to improve surgical outcomes while managing costs, the entry of more affordable robotic alternatives could accelerate adoption in middle-income countries and expand treatment options for patients who might otherwise lack access to advanced surgical care. The regulatory approvals in these four diverse nations—spanning Latin America, the Middle East, South Asia, and Africa—suggest a strategic approach to addressing global healthcare disparities through technological innovation.
